Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Qiagen ( (QGEN) ).
Qiagen N.V. has announced a synthetic share repurchase plan, where every 36 issued Qiagen shares are consolidated into 35 shares. This corporate action, which consolidates the shares held by Mr. Ross Levine from 465 to 16,273 common shares, was part of a strategic decision approved in June 2024 by the Annual General Meeting. This move may influence Qiagen’s market positioning and shareholder value by optimizing the share capital structure.
More about Qiagen
Qiagen N.V. is a biotechnology company based in the Netherlands, specializing in providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is prominently involved in the healthcare sector, focusing on the development and marketing of solutions to enable customers to gain valuable insights from the building blocks of life, DNA, RNA, and proteins.
YTD Price Performance: -0.02%
Average Trading Volume: 949,621
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $9.69B
Learn more about QGEN stock on TipRanks’ Stock Analysis page.
